Qualifications

MB BCh BAO Queen’s University Belfast 1999

PhD in Radiobiology Queen’s University Belfast 2010

Post Graduate Certificate of Education (Clinical Education-PGCE) Queen’s University Belfast 2014

Additional Training

Fellow in Prostate Cancer Radiation Oncology

Sunnybrook Health Sciences Centre, Toronto – 2011 - 2012

Professional bodies (Positions held in last 3 years)

Fellow of the Royal College of Radiologists of London FRCR 2011

Member of the Royal College of Physicians of Edinburgh (MRCP) 2003

Publications

Brand D., Tree A., Ostler P.,

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology. 2020

Mateo J., Porta N., McGovern U., et al. TOPARP-B

A phase II randomized trial of the poly (ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. Lancet Oncology 2019

Alayed, Y., Loblaw, A., Chu, W., (2019)

Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study. International Journal of Radiation Oncology Biology and Physics. 104, 1066-1073.

O’Neill, A., Osman, S., Jain, S. (2019)

Observed high incidence of prostatic calculi with the potential to act as natural fiducials for prostate image guided radiotherapy. Technical Innovations & Patient Support in Radiation Oncology 9, 35-40.

Crowther K., Cole, A., Shiels P., (2019)

A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brachytherapy combined with hypo-fractionated radiotherapy or hypo-fractionated radiotherapy alone for the treatment of localised prostate

Yang, L., Roberts, D., Takhar, M., (2018)

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 31, 182-189

Corey, G., Mohamed Yoosuf, A.B., Workman, G., (2018)

UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. Journal of Contemporary Brachytherapy 10, 238-245

King, R.B., Osman, S.O.S., Fairmichael, C., (2018)

Efficacy of a rectal spacer with prostate SABR—first UK experience. British Journal of Radiology 91

Hanna, G.G., Murray, L., Patel, R., (2018)

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical Oncology 30, 5-14

Jain, S., Lyons, C.A., Walker, S.M., (2018)

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Annals of Oncology 29, 215-222

King, R.B., McMahon, S.J., Hyland, W.B., (2017)

An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology. Cancer Nanotechnology 8

Lyons, C.A., King, R.B., Osman, S.O.S., (2017)

A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. Radiation Oncology 12

Helou, J., Thibault, I., Poon, I., (2017)

Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter. International Journal of Radiation Oncology Biology Physics 98, 419-427

Nicolae, A., Morton, G., Chung, H., (2017)

Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics 97, 822-829

Osman, S.O.S., Horn, S., Brady, D., (2017)

Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiation Oncology

Musunuru, H.B., Yamamoto, T., Klotz, L., (2016)

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. Journal of Urology 196, 1651-1658

Osman, S.O.S., Jeevanandam, P., Kanakavelu, (2016)

Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation. Radiation Oncology

Chen, R.C., Bryan Rumble, R., Andrew Loblaw, (2016)

Active surveillance for the management of localized prostate cancer (Cancer Care Ont. guideline): American society of clinical oncology clinical practice guideline endorsement. Journal of Clinical Oncology 34, 2182-96

O'neill, A.G.M., Jain, S., Hounsell, A.R., (2016)

Fiducial marker guided prostate radiotherapy: A review. British Journal of Radiology 89

Mohamed Yoosuf, A.B., Mitchell, D.M., Workman, G., (2015)

Sector analysis provides additional spatial information on the permanent prostate brachytherapy learning curve. Brachytherapy 14, 703-710

Klotz, L., Vesprini, D., Sethukavalan, P., (2015)

Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology 33, 272-277

Jain, S., Loblaw, A., Vesprini, D., (2015)

Gleason upgrading with time in a large prostate cancer active surveillance cohort. Journal of Urology 194, 79-84

Mateo, J., Carreira, S., Sandhu, S., (2015)

DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine 373, 1697-1708

Jain, S., Coulter, J.A., Butterworth, K.T., (2014)

Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiotherapy and Oncology 110, 342-347